Email Alert | RSS

Journal of Peking University (Health Sciences) ›› 2024, Vol. 56 ›› Issue (6): 980-986. doi: 10.19723/j.issn.1671-167X.2024.06.006

Previous Articles     Next Articles

Analysis of clinical features of ruccrent interstitial lung disease in patients with anti-EJ positive antisynthetase syndrome

Yujing ZHU, Lei WANG, Chengyin LYU, Wenfeng TAN, Miaojia ZHANG*()   

  1. Department of Rheumatology and Immunology, the First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China
  • Received:2024-08-01 Online:2024-12-18 Published:2024-12-18
  • Contact: Miaojia ZHANG E-mail:miaojia_zhang@163.com
  • Supported by:
    the Clinical Capacity Enhancement Project of the First Affiliated Hospital of Nanjing Medical University(JSPH-MC-2023-29)

RICH HTML

   

PDF (PC)

Abstract:

Objective: To summarize the clinical characteristics of 57 patients diagnosed with anti-glycyl tRNA synthetase (anti-EJ) positive antisynthetase syndrome (ASS), a subtype of anti-glycyl tRNA positive ASS, complicated by interstitial lung disease (ILD), and to investigate the factors asso-ciated with ILD recurrence. Methods: A retrospective analysis was conducted on the clinical data of 57 anti-EJ positive ASS patientswho were treated at the First Affiliated Hospital of Nanjing Medical University from January 1, 2020 to June 30, 2024. The data collected included demographic information, clinical characteristics, laboratory test results, chest CT findings, and pulmonary function tests. The characteristics of ILD recurrence were also analyzed. Results: All the 57 patients with anti-EJ positive ASS were diagnosed with ILD. The mean age at disease onset was (58.18±10.27) years, with a mean disease duration of 3.00 (2.00, 16.00) months. Among the patients, 70. 18% were female, 87.72% experienced a cough, 70. 18% had expectoration, 89.47% reported respiratory difficulties, and 14.04% developed respiratory failure. The results of pulmonary function test showed that the percentage of forced vital capacity (FVC) in the normal predicted value (FVC%), the percentage of forced expiratory volume in the first second (FEV1) in the normal predicted value (FEV1%) and the percentage of diffusion lung carbon monoxide (DLCO) in the normal predicted value (DLCO%) were 59.36±21.41, 58.34±19.46 and 58.17±27.95, respectively. The oxygenation index was (363.24±99.42) mmHg. Chest CT imaging showed that nonspecific interstitial pneumonia (NSIP) was the most common radiographic pattern. Among the 46 patients who completed a follow-up of more than 12 months, 21 cases (45.65%) showed recurrence of ILD. The average age of onset for the recurrence group was (61.38±8.63) years, while that for the non-recurrence group was (55.28±11.85) years, with a difference approaching statistical significance (P=0.056). Further analysis showed that the ESR (erythrocyte sedimentation rate) level was significantly higher in the recurrence group than in the non-recurrence group [(50.48±29.64) mm/h vs. 30.28±23.97) mm/h, P=0.025], and the IgM (immune globulin M) level was also significantly higher in the recurrence group (P=0.042). Moreover, the CD8+T proportion was significantly higher in the recurrence group than in the non-recurrence group (25.48±11.81 vs. 18.59± 8.53, P=0.027). Despite the fact that the recurrence group had a higher baseline age, higher ESR, IgM, and CD8+T proportion, multivariate binary logistic regression analysis showed that these indicators were not independent risk factors for ILD recurrence. Conclusion: ILD is the most common clinical manifestation in patients with anti-EJ positive ASS, with a significant impact on pulmonary function. Although the patients responded well to a combination of glucocorticoid and immunosuppressive therapies, the recurrence rate remains high, particularly in those with increased sputum production, and elevated ESR. Close monitoring and early intervention for high-risk patients are essential to improving long-term outcomes.

Key words: Antisynthetase syndrome, Interstitial lung disease, anti-glycyl tRNA antisynthetase antibody, Recurrence

CLC Number: 

  • R563

Figure 1

Flowchart of clinical data analysis anti-EJ, anti-glycyl tRNA synthetase; ASS, antisynthetase syndrome; ILD, interstitial lung disease."

Table 1

Clinical features between ruccrence group and non-ruccrence group in anti-EJ positive ASS-ILD patients"

Clinical parameters Overall (n=57) Ruccrence (n=21) Non-ruccrence (n=25) P
Female 40 (70.18) 17 (80.95) 18 (72.00) 0.514
Age/years 58.18±10.27 61.38±8.63 55.28±11.85 0.056
ILD diagnosis time/months 3.00 (2.00, 16.00) 3.00 (2.00, 10.00) 2.50 (1.75, 24.00) 0.461
Cough 50 (87.72) 20 (95.24) 21 (84.00) 0.351
Sputum 40 (70.18) 18 (85.71) 15 (60.00) 0.099
Dyspnea 51 (89.47) 19 (90.48) 23 (92.00) 1.000
Respiratory failure 8 (14.04) 2 (9.52) 3 (12.00) 1.000
Fever 13 (22.81) 3 (14.29) 7 (28.00) 0.306
Mechanic’s hands 16 (28.07) 5 (23.81) 7 (28.00) 1.000
DM rash 16 (28.07) 6 (28.57) 9 (36.00) 0.754
Myocardial injury 14 (24.56) 6 (28.57) 8 (32.00) 1.000
Myalgia 20 (35.09) 4 (19.05) 7 (28.00) 0.514
Arthritis 11 (19.30) 5 (23.81) 4 (16.00) 0.711
Ro-52 51 (89.47) 18 (85.71) 23 (92.00) 0.648
Treatment (baseline)
TAC 30 (52.63) 11 (52.38) 14 (56.00) 1.000
CYC 15 (26.32) 5 (23.81) 6 (24.00) 1.000
MMF 4 (7.18) 4 (19.05) 0 (0.00) 0.024
Glucocorticoid dosage/(mg/d) 63.68±45.73 72.14±50.01 53.40±28.32 0.118

Table 2

Comparison of baseline laboratory parameters and pulmonary function between the ruccrence group and non-ruccrence group"

Category Overall (n=57) Ruccrence (n=21) Non-ruccrence (n=25) P
WBC/(×109/L) 8.40±4.21 9.74±3.67 8.78±3.17 0.346
lymphocyte count/(×109/L) 1.42±0.87 1.34±0.60 1.56±1.13 0.423
ESR/(mm/h) 40.63±27.80 50.48±29.64 30.28±23.97 0.014
CRP/(mg/L) 12.77±16.48 12.74±14.96 9.85±12.33 0.476
SF/(μg/L) 302.34±253.00 282.96±215.12 256.89±184.98 0.665
CK/(U/L) 80.00 (32.00, 375.50) 45.00 (24.50, 78.00) 238.50 (32.50, 1 291.50) 0.428
LDH/(U/L) 292.00 (245.50, 378.00) 271.00 (244.50, 277.75) 368.00 (269.75, 419.75) 0.275
IgG/(g/L) 12.40 (9.86, 15.20) 11.35 (10.83, 13.13) 13.05 (10.33, 22.73) 0.193
IgM/(g/L) 1.87 (1.17, 3.06) 2.02 (1.62, 3.68) 1.68 (0.98, 2.85) 0.042
IgA/(g/L) 2.64±1.07 2.57±1.20 2.73±1.06 0.626
CD3+ T/% 61.17±12.41 59.98±17.00 61.77±9.33 0.654
CD4+ T/% 39.26±11.43 36.23±12.55 41.6±10.75 0.125
CD8+ T/% 21.36±10.38 25.48±11.81 18.59±8.53 0.027
Oxygen index/mmHg 363.24±99.42 360.69±99.58 386.11±106.34 0.477
FVC% 59.36±21.41 60.45±25.13 64.71±17.38 0.578
FEV1% 58.34±19.46 58.05±21.49 64.07±16.83 0.381
DLCO% 58.17±27.95 60.67±32.52 56.78±22.61 0.694

Table 3

Comparison of laboratory parameters at baseline and at reccurence in 21 patients with ASS"

Category Baseline Ruccrence P
WBC/(×109/L) 9.74±3.67 9.55±3.21 0.797
lymphocyte count/(×109/L) 1.34±0.50 1.20±0.62 0.462
Neutrophils count/(×109/L) 7.66±3.49 7.72±3.03 0.928
Hb/(g/L) 123.33±13.44 128.67±11.70 0.925
PLT/(×109/L) 269.95±77.29 258.17±69.44 0.422
CK/(U/L) 82.00 (45.00, 216.50) 93.00 (35.00, 134.00) 0.068
LDH/(U/L) 342.95±135.26 287.24±91.68 0.095
SF/(μg/L) 248.50 (145.80, 323.37) 314.32 (162.85, 314.32) 0.622
CRP/(mg/L) 7.98 (3.51, 10.85) 18.20 (7.26, 29.32) 0.053
ESR/(mm/h) 50.48±29.64 31.14±14.57 0.003
IgG/(g/L) 14.59±4.78 11.62±3.68 0.004
IgA/(g/L) 2.57±1.20 2.02±1.22 0.002
IgM/(g/L) 2.85±2.36 1.79±1.06 0.005

Table 4

Chest CT classification of ASS-ILD patients with positive anti-EJ antibodies"

Group Overall (n=57) Ruccrence (n=21) Non-ruccrence (n=25)
NISP 40 (70.18) 16 (76.19) 19 (76.00)
OP 4 (7.02) 1 (4.76) 1 (4.00)
UIP 6 (10.53) 2 (9.52) 3 (12.00)
NSIP+OP 2 (3.51) 0 (0.00) 1 (4.00)
NSIP+UIP 4 (7.02) 2 (9.52) 1 (4.00)
LIP 1 (1.75) 0 (0.00) 1 (4.00)

Table 5

Multifactorial binary Logistic analysis of ILD relapse"

Items β s t P OR OR(95%CI)
ESR 0.023 0.013 2.850 0.091 1.023 0.996, 1.050
IgM 0.203 0.293 0.482 0.488 1.226 0.690, 2.176
CD8+ T 0.065 0.036 3.273 0.070 1.067 0.995, 1.144
1 Aggarwal R , Cassidy E , Fertig N , et al. Patients with non-Jo-1 anti-tRNA synthetase autoantibodies have worse survival than Jo-1 positive patients[J]. Ann Rheum Dis, 2014, 73 (1): 227- 232.
doi: 10.1136/annrheumdis-2012-201800
2 Sreevilasan SK , Devarasetti P , Narahari NK , et al. Clinical profile and treatment outcomes in antisynthetase syndrome: A tertiary centre experience[J]. Rheumatol Adv Pract, 2021, 5 (Suppl 2): ii10- ii18.
3 Hamaguchi Y , Fujimoto M , Matsushita T , et al. Common and distinct clinical features in adult patients with anti-aminoacyl-tRNA synthetase antibodies: Heterogeneity within the syndrome[J]. PLoS One, 2013, 8 (4): e60442.
doi: 10.1371/journal.pone.0060442
4 Teel A , Lu J , Park J , et al. The role of myositis-specific autoantibodies and the management of interstitial lung disease in idiopathic inflammatory myopathies: A systematic review[J]. Semin Arthritis Rheum, 2022, 57, 152088.
doi: 10.1016/j.semarthrit.2022.152088
5 Zhang Y , Ge Y , Yang H , et al. Clinical features and outcomes of the patients with anti-glycyl tRNA synthetase syndrome[J]. Clin Rheumatol, 2020, 39 (8): 2417- 2424.
doi: 10.1007/s10067-020-04979-8
6 Watanabe K , Handa T , Tanizawa K , et al. Detection of antisynthetase syndrome in patients with idiopathic interstitial pneumonias[J]. Respir Med, 2011, 105 (8): 1238- 1247.
doi: 10.1016/j.rmed.2011.03.022
7 Sasano H , Hagiwara E , Kitamura H , et al. Long-term clinical course of anti-glycyl tRNA synthetase (anti-EJ) antibody-related interstitial lung disease pathologically proven by surgical lung biopsy[J]. BMC Pulm Med, 2016, 16 (1): 168.
doi: 10.1186/s12890-016-0325-y
8 Hozumi H , Fujisawa T , Nakashima R , et al. Efficacy of glucocorticoids and calcineurin inhibitors for anti-aminoacyl-trna synthetase antibody-positive polymyositis/dermatomyositis-associated interstitial lung disease: A propensity score-matched analysis[J]. J Rheumatol, 2019, 46 (5): 509- 517.
doi: 10.3899/jrheum.180778
9 Yorishima Y , Tominaga M , Fujimoto K , et al. Combination of prednisolone and calcineurin inhibitors prevents lung function decline in patients with anti-aminoacyl-tRNA synthetase antibody-positive polymyositis/dermatomyositis[J]. Kurume Med J, 2023, 69 (1/2): 19- 30.
10 Martínez-García EA , Lujano-Benítez AV , Gercía-De La Torre Ⅰ , et al. Good response to mycophenolate mofetil on treatment of interstitial lung disease in polymyositis associated with antisynthetase syndrome positive for anti-EJ and anti-Ro52 antibodies[J]. Clin Rheumatol, 2020, 39 (9): 2837- 2839.
doi: 10.1007/s10067-020-05075-7
11 Langlois V , Gillibert A , Uzunhan Y , et al. Rituximab and cyclophosphamide in antisynthetase syndrome-related interstitial lung disease: An observational retrospective study[J]. J Rheumatol, 2020, 47 (11): 1678- 1686.
doi: 10.3899/jrheum.190505
12 Liu Y , Liu X , Xie M , et al. Clinical characteristics of patients with anti-EJ antisynthetase syndrome associated interstitial lung disease and literature review[J]. Respir Med, 2020, 165, 105920.
doi: 10.1016/j.rmed.2020.105920
13 Connors GR , Christopher-Stine L , Oddis CV , et al. Interstitial lung disease associated with the idiopathic inflammatory myopathies: What progress has been made in thepast 35 years[J]. Chest, 2010, 138 (6): 1464- 1474.
doi: 10.1378/chest.10-0180
14 Bohan A , Peter JB . Polymyositis and dermatomyositis (first of two parts)[J]. N Engl J Med, 1975, 292 (7): 344- 347.
doi: 10.1056/NEJM197502132920706
15 Raghu G , Remy-Jardin M , Richeldi L , et al. Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: An official ATS/ERS/JRS /ALAT clinical practice guideline[J]. Am J Respir Crit Care Med, 2022, 205 (9): e18- e47.
doi: 10.1164/rccm.202202-0399ST
16 Targoff IN . Autoantibodies to aminoacyl-transfer RNA synthetases for isoleucine and glycine. Two additional synthetases are antigenic in myositis[J]. J Immunol, 1990, 144 (5): 1737- 1743.
doi: 10.4049/jimmunol.144.5.1737
17 Tang HS, Tang IYK, Ho RTC, et al. Clinical heterogeneity and prognostic factors of anti-synthetase syndrome: A multi-centered retrospective cohort study[J]. Rheumatology (Oxford), 2023 (2023-12-14)[2024-09-01]. https://Doi.org/10.1093/rheumatology/kead671.
18 García-Bravo L , Calle-Rubio M , Fernández-Arquero M , et al. Association of anti-SARS-COV-2 vaccine with increased incidence of myositis-related anti-RNA-synthetases auto-antibodies[J]. J Transl Autoimmun, 2022, 5, 100160.
doi: 10.1016/j.jtauto.2022.100160
19 Irie Y , Wakabayashi H , Matuzawa Y , et al. A case of anti-synthetase syndrome with anti-glycyl tRNA synthetases antibody de-veloped after COVID-19[J]. Cureus, 2024, 16 (4): e58004.
20 Shimizu H , Matsumoto H , Sasajima T , et al. New-onset dermatomyositis following COVID-19: A case report[J]. Front Immunol, 2022, 13, 1002329.
doi: 10.3389/fimmu.2022.1002329
21 Peña C , Kalara N , Velagapudi P . A case of antisynthetase syndrome in the setting of SARS-Cov-2 infection[J]. Cureus, 2023, 15 (6): e40588.
22 Elsayed M , Abdelgabar A , Karmani J , et al. A case of antisynthetase syndrome initially presented with interstitial lung disease mimicking COVID-19[J]. J Med Cases, 2023, 14 (1): 25- 30.
doi: 10.14740/jmc4031
23 Tranah E , MacBrayne A , Bhadauria N , et al. A case of antisynthetase syndrome presenting solely with life-threatening interstitial lung disease[J]. Clin Med (Lond), 2023, 23 (1): 85- 87.
24 周云, 吕成银, 尤含笑, 等. 不同抗体亚型抗合成酶综合征并发间质性肺疾病临床特征分析[J]. 中华风湿病学杂志, 2024, 28 (8): 538- 544.
[1] Jingwen LAN, Zhe CHEN, Yongjing CHENG, Like ZHAO. Clinical characteristics, efficacy and safety of antifibrotic agents in elderly patients with connective tissue disease-associated interstitial lung disease [J]. Journal of Peking University (Health Sciences), 2025, 57(6): 1101-1106.
[2] Fengyi HU, Qingyang MENG, Nayun CHEN, Jianing WANG, Zhenlong LIU, Yong MA, Yuping YANG, Xi GONG, Cheng WANG, Ping LIU, Weili SHI. Clinical efficacy of arthroscopic medial patellofemoral complex reconstruction for recurrent patellar dislocation with high-grade trochlear dysplasia [J]. Journal of Peking University (Health Sciences), 2025, 57(5): 947-955.
[3] Yukai LI, Hongyan WANG, Liang LUO, Yun LI, Chun LI. Clinical significance of antiphospholipid antibodies in Behcet disease with thrombosis [J]. Journal of Peking University (Health Sciences), 2024, 56(6): 1036-1040.
[4] Rui YAN, Dan KE, Yan ZHANG, Li LI, Huanran SU, Wei CHEN, Mingxia SUN, Xiaomin LIU, Liang LUO. Diagnostic significance of serum chemokine CXCL-10 and Krebs von den lungen-6 level in patients with rheumatoid arthritis associated interstitial lung disease [J]. Journal of Peking University (Health Sciences), 2024, 56(6): 956-962.
[5] Yuqing LI,Biao WANG,Peng QIAO,Wei WANG,Xing GUAN. Medium to long-term efficacy of tension-free vaginal tape procedure in the treatment of female recurrent stress urinary incontinence [J]. Journal of Peking University (Health Sciences), 2024, 56(4): 600-604.
[6] Zhanhong LAI,Jiachen LI,Zelin YUN,Yonggang ZHANG,Hao ZHANG,Xiaoyan XING,Miao SHAO,Yuebo JIN,Naidi WANG,Yimin LI,Yuhui LI,Zhanguo LI. A unicenter real-world study of the correlation factors for complete clinical response in idiopathic inflammatory myopathies [J]. Journal of Peking University (Health Sciences), 2024, 56(2): 284-292.
[7] Qi WU,Yue-ming CAI,Juan HE,Wen-di HUANG,Qing-wen WANG. Correlation between dyslipidemia and rheumatoid arthritis associated interstitial lung disease [J]. Journal of Peking University (Health Sciences), 2023, 55(6): 982-992.
[8] Wen-gen LI,Xiao-dong GU,Rui-qiang WENG,Su-dong LIU,Chao CHEN. Expression and clinical significance of plasma exosomal miR-34-5p and miR-142-3p in systemic sclerosis [J]. Journal of Peking University (Health Sciences), 2023, 55(6): 1022-1027.
[9] Chieko MORIMOTO,Yi-qin WANG,Rong ZHOU,Jian-liu WANG. Clinical analysis of fertility-sparing therapy of patients with complex atypical hyperplasia and endometrial cancer [J]. Journal of Peking University (Health Sciences), 2022, 54(5): 936-942.
[10] Yue WANG,Shuang ZHANG,Hong ZHANG,Li LIANG,Ling XU,Yuan-jia CHENG,Xue-ning DUAN,Yin-hua LIU,Ting LI. Clinicopathological features and prognosis of hormone receptor-positive/human epidermal growth factor receptor 2-negative breast cancer [J]. Journal of Peking University (Health Sciences), 2022, 54(5): 853-862.
[11] Su-hua CHEN,Jun YANG,Xin CHEN,Chen-long YANG,Jian-jun SUN,Guo-zhong LIN,Tao YU,Xin YANG,Yun-feng HAN,Chao WU,Yu SI,Kai-ming MA. Surgical treatment of large and giant recurrent meningiomas near the middle and posterior third part of the superior sagittal sinus with extracranial invading [J]. Journal of Peking University (Health Sciences), 2022, 54(5): 1006-1012.
[12] ZHANG Pu-li,YANG Hong-xia,ZHANG Li-ning,GE Yong-peng,PENG Qing-lin,WANG Guo-chun,LU Xin. Value of serum YKL-40 in the diagnosis of anti-MDA5-positive patients with dermatomyositis complicated with severe pulmonary injury [J]. Journal of Peking University (Health Sciences), 2021, 53(6): 1055-1060.
[13] LIU Lei,QIN Yan-chun,WANG Guo-liang,ZHANG Shu-dong,HOU Xiao-fei,MA Lu-lin. Strategy of reoperation for pheochromocytoma and paraganglioma [J]. Journal of Peking University (Health Sciences), 2021, 53(4): 793-797.
[14] XIA Fang-fang,LU Fu-ai,LV Hui-min,YANG Guo-an,LIU Yuan. Clinical characteristics and related factors of systemic lupus erythematosus with interstitial pneumonia [J]. Journal of Peking University (Health Sciences), 2021, 53(2): 266-272.
[15] Huan-bin YU,Wen-jie WU,Xiao-ming LV,Yan SHI,Lei ZHENG,Jian-guo ZHANG. 125I seed brachytherapy for recurrent salivary gland carcinoma after external radiotherapy [J]. Journal of Peking University (Health Sciences), 2020, 52(5): 919-923.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
Copyright © Journal of Peking University (Health Sciences), All Rights Reserved.
Powered by Beijing Magtech Co. Ltd